Chris Boerner, COO of Bristol-Myers, said the launches will expand the uses of some of its already approved drugs and include some new cell therapy treatments for cancer and a treatment for relapsing multiple sclerosis.
Fedratinib, a treatment for a rare bone marrow cancer, is one of the drugs the company plans to launch in the next year. It was approved by the FDA in August.
Bristol-Myers expects Ozanimod, a treatment for relapsing multiple sclerosis, to be approved by March, Business Insider reported.
It also expects the FDA to make a decision by April on luspatercept, a drug that treats anemia in people with blood disorders.
Bristol-Myers is looking to expand the use of its best-selling cancer immunotherapy drugs, Opdivo and Yervoy, to treat non-small cell lung cancer and expects the FDA to make a decision by May 15, according to Business Insider.
The drugmaker also plans to launch liso-cell, a cell therapy designed to treat large B-cell lymphoma that it gained when it acquired Celgene.
It plans to launch TYK2, a treatment for psoriasis, after getting data from its late-stage trial in the first half of 2020.
Ide-cel, a cell therapy to treat multiple myeloma, should be submitted to the FDA in the first half of 2020, according to Business Insider.
And Bristol-Myers plans to launch CC-486, a treatment for myeloid leukemia.
Read the full article here.
More articles on pharmacy:
Drug shortages update: 5 things to know
Grocery store pharmacies across the country finding it harder to stay in business
AbbVie to donate $1M of drug China says will combat coronavirus
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.